Literature DB >> 2848313

Humoral and cellular responses to Pneumocystis carinii, CMV, and herpes simplex in patients with AIDS and in controls.

B Hofmann1, P B Nielsen, N Odum, J Gerstoft, P Platz, L P Ryder, A G Poulsen, L Mathiesen, E Dickmeiss, B Norrild.   

Abstract

The titers of IgG and IgA to Pneumocystis carinii in 36 AIDS patients did not differ significantly from those in 31 controls. Only 2/15 patients (13%) with P. carinii pneumonia (PCP) had titers of IgM antibodies greater than or equal to 5, which is significantly less frequent than in 32 controls (62%) and in 21 AIDS patients without PCP (43%). The risk of PCP was 5 times higher in patients without IgM antibodies to P. carinii than in patients who had these antibodies. A significantly higher percentage of those without PCP (57%) showed increasing titers of IgM antibodies to P. carinii in the second of paired samples taken about 6 months apart, compared with whose with PCP (9%; p = 0.05). All patients had high titers of antibodies to CMV and HSV and normal total concentrations of immunoglobulins. None of the patients responded in lymphocyte transformation to P. carinii, CMV, or HSV antigens. There is no obvious explanation to the selective lack of IgM antibodies to P. carinii in patients with PCP. Lack of IgM antibodies may be a marker for an immunodeficiency to P. carinii.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2848313     DOI: 10.3109/00365548809032473

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  9 in total

Review 1.  Immunological features of Pneumocystis carinii infection in humans.

Authors:  P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Human immunodeficiency virus-infected patients with prior Pneumocystis pneumonia exhibit increased serologic reactivity to several major surface glycoprotein clones.

Authors:  K R Daly; J V Koch; N J Shire; L Levin; P D Walzer
Journal:  Clin Vaccine Immunol       Date:  2006-10

3.  Decreased production of local immunoglobulin A to Pneumocystis carinii in bronchoalveolar lavage fluid from human immunodeficiency virus-positive patients.

Authors:  A Jalil; P Moja; C Lambert; M Perol; L Cotte; J M Livrozet; A Boibieux; J M Vergnon; F Lucht; R Tran; C Contini; C Genin
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

4.  Purification and characterization of a major human Pneumocystis carinii surface antigen.

Authors:  B Lundgren; G Y Lipschik; J A Kovacs
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

5.  Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens.

Authors:  K Daly; J Koch; N Respaldiza; C de la Horra; M A Montes-Cano; F J Medrano; J M Varela; E J Calderon; P D Walzer
Journal:  Clin Microbiol Infect       Date:  2009-03-21       Impact factor: 8.067

6.  Antibody response to a major human Pneumocystis carinii surface antigen in patients without evidence of immunosuppression and in patients with suspected atypical pneumonia.

Authors:  B Lundgren; M Lebech; K Lind; J O Nielsen; J D Lundgren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-02       Impact factor: 3.267

7.  Antibody response to Pneumocystis jirovecii major surface glycoprotein.

Authors:  Kieran R Daly; Laurence Huang; Alison Morris; Judy Koch; Kristina Crothers; Linda Levin; Shary Eiser; Supriya Satwah; Patricia Zucchi; Peter D Walzer
Journal:  Emerg Infect Dis       Date:  2006-08       Impact factor: 6.883

8.  Serologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms.

Authors:  Robert J Blount; Leah G Jarlsberg; Kieran R Daly; William Worodria; J Lucian Davis; Adithya Cattamanchi; Kpandja Djawe; Alfred Andama; Judith Koch; Peter D Walzer; Laurence Huang
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

9.  Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci.

Authors:  Kieran R Daly; Judy Koch; Linda Levin; Peter D Walzer
Journal:  Emerg Infect Dis       Date:  2004-05       Impact factor: 6.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.